Calcipotriol 50micrograms/g with Betamethasone 0.05% (Dovobet Gel®)
Scalp psoriasis: usual duration of treatment is 4 weeks
Mild to moderate plaque psoriasis, apply once daily to max. 30% of body surface (max. 15 g daily) for 8 weeks
Calcipotriol 50micrograms/g with Betamethasone 0.05% (Dovobet ointment ®)
4 weeks therapy then assess
Maximum 15g per day or 100g per week.
Step down to calcipotrol oint as per NICE CG153
Calcipotriol 50micrograms/g with Betamethasone 0.05mg/g (Enstilar®)
Cutaneous foam formulation
The recommended treatment period is 4 weeks
Maximum 15g per day
Excipients include liquid paraffin and butane-
Extremely flammable aerosol
Calcitriol 3micrograms/g (Silkis®)
For delicate areas,face and flexures
Coal tar lotion 5% (Exorex®)
Coal Tar Solution 2.5%, Arachis (peanut) Oil extract of Coal Tar 7.5%, Tar 7.5%, Cade Oil 7.5%, Liqiud Paraffin 35% (Polytar Emollient®)
contains peanut oil
All Strengths. Specialist Recommendation
Tars - bath preparations (Psoriderm emulsion®)
Oral retinoids for psoriasis
Non Formulary Items
Coal Tar 10% (Carbo-Dome®)
Coal Tar in Lassars Paste
Coal Tar in Unguentum M
Dithranol Ointment BP
Dithranol Paste BP
Salicylic Acid 3% w/w, Sulphur 3% w/w in Aqueous Cream
Salicylic Acid in White Soft Paraffin
Tars (Zinc and Coal Tar Paste®)
Tars - bath preparations
Tars - bath preparations (Pinetarsol®)
Tazarotene 0.05% (Zorac®)
Zinc and Salicylic Acid Paste BP
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
High Cost Medicine
Cancer Drugs Fund
Traffic Light Status Information
Prescribing in children
The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.
The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications.
Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.
Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements.
Medicines for initiation and maintenance prescribing by Specialists only
Non-formulary medicines- medicines not recommended for routine primary care prescribing.
Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information.